ALERE INC.
DelistedCIK 1145460fmd_002MNR7JVZ2Q5EM7KS7FYHZGKRManufacturing · In Vitro & In Vivo Diagnostic SubstancesTemplate: Standard
Coverage: Jan 01, 2008 to Jun 30, 2017, 34 periods
| Line item | FY2008 | FY2009 | FY2010 | FY2011 | FY2012 | FY2013 | FY2014 | FY2015 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|
| Total revenues | 1,583 | 1,923 | 2,155 | – | 2,394 | 2,609 | 2,577 | 2,456 | 2,376 |
| Cost of revenue | 729 | 868 | 1,021 | – | 1,148 | 1,297 | 1,364 | 1,347 | 1,286 |
| Gross profit | 854 | 1,054 | 1,135 | – | 1,246 | 1,312 | 1,213 | 1,108 | 1,090 |
| Research and development | 112 | 113 | 133 | – | 182 | 159 | 145 | 119 | 112 |
| Selling, general and administrative | 677 | 799 | 946 | – | 904 | 1,001 | 966 | 809 | 967 |
| Total operating expenses | – | – | – | 1,683 | – | – | – | – | – |
| Operating income | 65 | 146 | (951) | – | 160 | 147 | 95 | 130 | 15 |
| Interest expense | 101 | 107 | 139 | – | 240 | 255 | 209 | 217 | 172 |
| Other non-operating income (expense) | (2) | 1 | 23 | – | 11 | (11) | (3) | 3 | 5 |
| Income before taxes | (38) | 40 | (1,068) | – | (69) | (120) | (118) | (85) | (152) |
| Income tax expense | (17) | (16) | (30) | – | (11) | (45) | 71 | (54) | 35 |
| Net income from continuing operations | (21) | 32 | (1,027) | – | (45) | (58) | (171) | (15) | (137) |
| Net income | (22) | 34 | (1,017) | – | (78) | (75) | (33) | 204 | (138) |
| Net income to common shareholders | (36) | 11 | (1,042) | – | (100) | (96) | (54) | 182 | (159) |